Browse the corpus

Kaposi varicelliform eruption (KVE), also called eczema herpeticum, is a disseminated cutaneous infection caused most commonly by herpes simplex virus type 1, and less frequently by type 2. Individuals with preexisting skin barrier disruption, such as atopic dermatitis, Darier disease, pemphigus, or Hailey-Hailey disease, are at increased risk. The impaired epidermal barrier and reduced innate immune defenses create an environment conducive to widespread viral replication. Clinically, KVE presents as clusters of monomorphic, dome-shaped vesiculopustules that evolve into punched-out erosions with hemorrhagic crusting. Lesions often appear abruptly, spreading rapidly across sites of prior dermatitis. Systemic features such as fever, lymphadenopathy, and malaise are common, and ocular or visceral involvement may occur in severe cases. Without timely recognition and treatment, the eruption can progress to life-threatening systemic disease. Complications include secondary bacterial superinfection, most often with Staphylococcus aureus or Streptococcus pyogenes, which may lead to cellulitis, abscess, or bacteremia. Ocular extension can result in herpetic keratoconjunctivitis and permanent visual loss. Systemic dissemination of herpes simplex virus may cause encephalitis, hepatitis, or multiorgan failure, with mortality rates approaching 10% in untreated cases. Prompt systemic antiviral therapy with acyclovir or valacyclovir is the cornerstone of management. Supportive care, monitoring for bacterial infections, and ophthalmologic evaluation are critical when periocular disease is present. Early recognition, patient education, and optimization of underlying dermatoses significantly reduce recurrence and morbidity. This activity will review the epidemiology, genetics, clinical presentation, complications, and management of Kaposi varicelliform eruption. Participants will gain the knowledge and strategies needed to recognize KVE early, implement evidence-based therapy, and collaborate across disciplines to improve patient outcomes. Objectives: Identify the clinical signs and symptoms of Kaposi varicelliform eruption to ensure prompt diagnosis. Differentiate Kaposi varicelliform eruption from other vesicular skin infections or dermatological conditions. Screen patients with underlying skin diseases, such as atopic dermatitis, for early signs of viral dissemination.

Identify the clinical signs and symptoms of Kaposi varicelliform eruption to ensure prompt diagnosis. Differentiate Kaposi varicelliform eruption from other vesicular skin infections or dermatological conditions. Screen patients with underlying skin diseases, such as atopic dermatitis, for early signs of viral dissemination. Collaborate with the interprofessional team to educate, treat, and monitor patients with Kaposi varicelliform eruption to improve patient outcomes. Access free multiple choice questions on this topic.

Kaposi varicelliform eruption (KVE), also known as eczema herpeticum, is a disseminated skin infection usually caused by herpes simplex virus that typically leads to localized vesicular eruptions in patients with an underlying cutaneous disease. Although rare, it is a potentially life-threatening disorder.[1][2][3] Most cases occur in patients with atopic dermatitis.[4][5] However, Kaposi varicelliform eruption has been associated with other skin conditions such as pemphigus foliaceus, ichthyosis vulgaris, bullous pemphigoid, Darier disease,[6] Grover disease, Hailey-Hailey disease, dyskeratosis follicularis, mycosis fungoides, Sézary syndrome, psoriasis, pityriasis rubra pilaris, rosacea, seborrheic dermatitis, allergic and irritant contact dermatitis, second-degree burns, and skin grafts.[7] Clinical manifestations of Kaposi varicelliform eruption include widespread clusters of umbilicated vesicles and pustules that evolve into crusted skin erosions (see Image. Kaposi Varicelliform Eruption). The most frequently affected sites are the trunk, neck, and head. Diagnosis is made primarily on clinical findings. In inconclusive cases, the Tzanck smear, viral cultures, skin biopsy, or detection of viral DNA by polymerase chain reaction may be useful. Antiviral therapy may be effective, but it should be initiated promptly after diagnosis to reduce morbidity and mortality.

Kaposi varicelliform eruption is primarily caused by herpes simplex virus type 1; however, other viral agents, such as herpes simplex virus type 2, coxsackie virus A16, vaccinia virus, varicella zoster virus, and variola virus (smallpox), have also been implicated in its pathogenesis.

Kaposi varicelliform eruption is a rare condition first described in 1887 by Moritz Kaposi. This condition occurs more frequently in children due to its relationship with atopic dermatitis; however, adult cases are also reported. The incidence is not precisely known due to its rarity and the absence of a large case series.[8][9] The disease equally affects men and women and does not appear to have a specific ethnic predominance.

Kaposi varicelliform eruption was initially assumed to be secondary to a fungal infection. However, the finding of cytoplasmic inclusion bodies on histological examination suggests a viral origin. The mechanisms underlying the pathogenesis of viral reactivation in Kaposi varicelliform eruption remain incompletely understood. A defective skin barrier in conjunction with an immune deficiency contributes to the development of the disease. Both cell-mediated and humoral immunity dysfunction are implicated. In addition, cytokines released by type 2 helper T cells in atopic dermatitis also contribute.[10] Results from recent studies indicate a genetic contribution to the pathogenesis. Reports describe KVE occurring in sun-damaged or barrier-damaged skin, including peeling or injured areas.[11][12]

A skin biopsy is not required to confirm a diagnosis; however, if performed, histological findings may include intraepidermal blisters, acantholysis, multinucleated giant cells with intranuclear inclusions, and ballooning degeneration of keratinocytes.

Patients with Kaposi varicelliform eruption present with a sudden skin eruption of painful clusters of umbilicated vesicles and pustules. These vesiculopustules often evolve into crusted, hemorrhagic, punched-out skin erosions that may enlarge and coalesce into extensive denuded areas, susceptible to bacterial infection. The distribution of affected skin reflects skin barrier impairment since the eruption typically begins in areas of underlying dermatosis. This initial topographic distribution can delay diagnosis because the eruption is often mistaken for another condition. Kaposi varicelliform eruption may be associated with systemic symptoms, such as malaise, fever, and lymphadenopathy. In addition, the disease can be complicated by multiorgan involvement, mainly of the central nervous system, liver, lungs, gastrointestinal tract, and adrenal glands.

The diagnosis of Kaposi varicelliform eruption is primarily based on clinical examination, although several laboratory tests can be helpful.[13][14] A Tzanck smear, performed by scraping the floor of an opened vesicle and staining with Wright-Giemsa stain, may demonstrate multinucleated giant cells. The test is inexpensive, easily applicable, and rapid to perform. However, this method has low sensitivity and does not differentiate between herpes simplex virus types 1 and 2, or varicella-zoster virus. Viral culture and direct fluorescent antibody staining on Tzanck smear are the most reliable techniques for herpes simplex virus detection. A skin biopsy or polymerase chain reaction may be performed in case of atypical, equivocal, or chronic lesions. Histological examination may confirm the diagnosis in uncertain cases, whereas the polymerase chain reaction detects viral DNA.

Treatment of Kaposi varicelliform eruption must be immediate since it is a potentially life-threatening disease. Antiviral therapy reduces morbidity and prevents complications. Nucleoside analogs are the antiviral agents most commonly used because they inhibit viral DNA replication.[15][16][17] Acyclovir is the most widely studied and prescribed drug for Kaposi varicelliform eruption. High-dose intravenous acyclovir is often necessary for disease control. The severity of the disease determines whether oral or intravenous treatment is required. The following dosing regimen is preferred: Oral acyclovir: 200 mg 5 times daily or 400 mg 3 times daily for mild to moderate disease Pediatric dosing: 40–80 mg/kg/day divided into 3–4 doses (maximum 1 g/day) Intravenous acyclovir: 10–15 mg/kg every 8 hours for severe or systemic disease Most patients experience resolution of the skin lesions within several days. Prophylactic treatment with systemic antibiotics is recommended to prevent secondary bacterial infection.

Kaposi varicelliform eruption is a serious condition that could be fatal. The disease may occur as a primary or a recurrent infection. The primary form primarily affects children, is usually disseminated, and is associated with systemic symptoms and life-threatening complications such as bacterial sepsis, viremia, and multiorgan involvement. The recurrent form occurs in adults and is usually a milder, more localized form that generally presents without viremia. Septicemia from secondary bacterial infection of cutaneous lesions also increases morbidity and mortality. The most common species isolated from patients with Kaposi varicelliform eruption are Staphylococcus aureus, group A β-hemolytic streptococcus, Peptostreptococcus, and Pseudomonas aeruginosa. Ocular disease can occur if herpes simplex virus–associated Kaposi varicelliform eruption affects the face. Ocular manifestations include uveitis, conjunctivitis, keratitis, and blepharitis. Herpetic keratitis is the most serious ophthalmological sequela, which may lead to vision loss from corneal scarring.

The principal cutaneous complications of Kaposi varicelliform eruption are secondary bacterial infections, most commonly due to Staphylococcus aureus or Streptococcus pyogenes. Such superinfections may evolve into cellulitis, abscess formation, or systemic bacteremia, increasing morbidity and prolonging the disease course. Extensive erosions and chronic ulceration often delay reepithelialization and may give rise to postinflammatory dyspigmentation and permanent scarring, particularly in cases of widespread involvement. Ocular complications represent an additional and clinically significant concern; periocular extension can precipitate herpetic keratoconjunctivitis, which, in the absence of urgent intervention, may culminate in irreversible visual impairment. Systemic dissemination of herpes simplex virus in the context of KVE, although uncommon, is a life-threatening complication. Hematogenous spread may produce herpetic meningoencephalitis, fulminant hepatitis, or multiorgan failure, with mortality rates of up to 10% in untreated individuals. Patients at most significant risk include infants, immunocompromised hosts, and those with profound cutaneous barrier dysfunction, most notably in association with atopic dermatitis, pemphigus, or other blistering disorders. Importantly, even with appropriate systemic antiviral therapy, recurrent episodes may occur, especially among patients with uncontrolled inflammatory dermatoses or persistent immunosuppression.

Effective prevention of Kaposi varicelliform eruption requires optimizing management of underlying dermatoses and educating patients and caregivers. Individuals with chronic conditions such as atopic dermatitis, Darier disease, pemphigus, or erythroderma should be counseled about their elevated risk for KVE, especially during outbreaks of herpes simplex virus. Epidemiologic data indicate that approximately 1.4% to 3% of patients with atopic dermatitis may develop eczema herpeticum (KVE form), particularly in pediatric populations. Registry data from Germany show that 21.8% of patients with moderate to severe atopic dermatitis experienced at least 1 KVE episode, and more than half (54.9%) had multiple episodes. Patient education should emphasize early recognition of prodromal signs, such as the rapid onset of monomorphic vesiculopustules, fever, or malaise, and the critical need for immediate medical evaluation. Barrier-protective measures, such as avoiding contact with active herpes simplex lesions, rigorous hygiene, and judicious use of immunosuppressants, are key deterrents to the spread of herpes simplex virus. Clinicians should personalize instruction for high-risk groups, including patients with immunosuppression and children living in the same household, and encourage prompt systemic antiviral treatment when symptoms arise. Evidence-based counseling enhances adherence, reduces morbidity, and may prevent life-threatening systemic complications.

Kaposi varicelliform eruption should be accurately diagnosed because delayed recognition can lead to adverse outcomes. Although there is no consensus on the optimal therapeutic approach, early initiation of antiviral therapy in combination with systemic antibiotics is crucial.

A patient with Kaposi varicelliform eruption may present to any interprofessional team member and should be referred immediately to a dermatologist. If ocular involvement is present, an ophthalmology consult is necessary. Treatment of Kaposi varicelliform eruption must be immediate because it is a potentially life-threatening disease. Antiviral therapy is effective in reducing morbidity and preventing complications. Acyclovir is the most widely studied and prescribed agent for Kaposi varicelliform eruption. High-dose intravenous acyclovir is often necessary for disease control, and a pharmacist should be involved to verify dosing and perform medication reconciliation. Most patients achieve resolution of the skin lesions over several days. Prophylactic systemic antibiotics are recommended to prevent secondary bacterial infection. Clinicians need to be aware of the signs of adverse drug reactions and closely monitor treatment response. These patients need close monitoring until the lesions have resolved, and management by an interprofessional team is the optimal approach.[18]